News

News

WIB_icon

New Target Holds Potential for Treatment of Common Anemia

Lexaptepid, an anti-hepcidin therapy, may be the first viable treatment option for patients with anemia of inflammation, according to the results of an experimental...

Good, But Not Optimal – HSCT Match Possible for Most Patients

For patients with certain blood cancers or other diseases, hematopoietic stem cell transplants (HSCT) are potentially lifesaving therapies. While the majority of patients are...

Ruxolitinib Shows Promise in Polycythemia Vera

Ruxolitinib, a JAK1/2 inhibitor approved by the FDA for the treatment of myelofibrosis, also has activity in another myeloproliferative neoplasm, polycythemia vera, according to...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.